Kohei Shitara

35.3k total citations · 12 hit papers
504 papers, 14.2k citations indexed

About

Kohei Shitara is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Kohei Shitara has authored 504 papers receiving a total of 14.2k indexed citations (citations by other indexed papers that have themselves been cited), including 369 papers in Oncology, 356 papers in Pulmonary and Respiratory Medicine and 127 papers in Surgery. Recurrent topics in Kohei Shitara's work include Gastric Cancer Management and Outcomes (310 papers), Colorectal Cancer Treatments and Studies (185 papers) and Gastrointestinal Tumor Research and Treatment (97 papers). Kohei Shitara is often cited by papers focused on Gastric Cancer Management and Outcomes (310 papers), Colorectal Cancer Treatments and Studies (185 papers) and Gastrointestinal Tumor Research and Treatment (97 papers). Kohei Shitara collaborates with scholars based in Japan, United States and South Korea. Kohei Shitara's co-authors include Hiroyoshi Nishikawa, Yosuke Togashi, Akihito Kawazoe, Kei Muro, Toshihiko Doi, Hyun Cheol Chung, Yoshiaki Nakamura, Eric Van Cutsem, Atsushi Ohtsu and Takeshi Kuwata and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Kohei Shitara

480 papers receiving 14.1k citations

Hit Papers

Regulatory T cells in cancer immunosuppression — implicat... 2017 2026 2020 2023 2019 2020 2019 2020 2021 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
    2019 1.1k citations Kohei Shitara, Hiroyoshi Nishikawa et al. profile →
  2. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
    2020 802 citations Kohei Shitara, Yung‐Jue Bang et al. profile →
  3. PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
    2019 692 citations Akinori Sasaki, Yoshiaki Nakamura et al. profile →
  4. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
    2020 567 citations Takashi Kojima, Akihito Kawazoe et al. Journal of Clinical Oncology profile →
  5. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
    2021 449 citations Yelena Y. Janjigian, Akihito Kawazoe et al. profile →
  6. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
    2017 391 citations Manish A. Shah, Eric Van Cutsem et al. profile →
  7. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
    2017 362 citations Toshihiko Doi, Kohei Shitara et al. profile →
  8. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
    2023 342 citations Kohei Shitara, Florian Lordick et al. profile →
  9. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
    2023 213 citations Yelena Y. Janjigian, Akihito Kawazoe et al. profile →
  10. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
    2021 189 citations Yoshiaki Nakamura, Akihito Kawazoe et al. profile →
  11. Claudin 18.2 as a novel therapeutic target
    2024 73 citations Izuma Nakayama, Yoshiaki Nakamura et al. profile →
  12. Gastric cancer
    2025 17 citations Izuma Nakayama, Kohei Shitara et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kohei Shitara Japan 55 9.3k 6.9k 3.3k 2.3k 2.2k 504 14.2k
Toshihiko Doi Japan 62 9.3k 1.0× 6.4k 0.9× 3.6k 1.1× 2.0k 0.9× 2.6k 1.2× 424 14.4k
Jayesh Desai Australia 45 7.7k 0.8× 4.9k 0.7× 2.0k 0.6× 1.1k 0.5× 3.5k 1.5× 325 13.4k
Josef Rüschoff Germany 51 8.9k 1.0× 6.2k 0.9× 3.4k 1.0× 712 0.3× 4.1k 1.8× 223 15.3k
Kosei Hirakawa Japan 63 7.6k 0.8× 3.3k 0.5× 3.2k 1.0× 1.7k 0.7× 4.6k 2.1× 590 14.2k
Sara Lonardi Italy 50 10.9k 1.2× 4.0k 0.6× 3.2k 1.0× 1.3k 0.6× 2.0k 0.9× 473 13.9k
Akira Sawaki Japan 44 6.3k 0.7× 7.4k 1.1× 4.7k 1.4× 409 0.2× 1.9k 0.9× 150 11.8k
Huamin Wang United States 74 11.5k 1.2× 4.0k 0.6× 4.3k 1.3× 2.0k 0.9× 5.6k 2.5× 256 17.9k
Hans Prenen Belgium 41 4.0k 0.4× 2.6k 0.4× 1.3k 0.4× 1.3k 0.6× 2.6k 1.2× 207 8.6k
Ho Yeong Lim South Korea 58 6.6k 0.7× 5.7k 0.8× 3.6k 1.1× 1.0k 0.5× 3.5k 1.6× 369 15.0k
Andrew M. Lowy United States 58 7.5k 0.8× 2.6k 0.4× 4.3k 1.3× 1.3k 0.6× 4.1k 1.8× 248 12.6k

Countries citing papers authored by Kohei Shitara

Since Specialization
Citations

This map shows the geographic impact of Kohei Shitara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kohei Shitara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kohei Shitara more than expected).

Fields of papers citing papers by Kohei Shitara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kohei Shitara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kohei Shitara. The network helps show where Kohei Shitara may publish in the future.

Co-authorship network of co-authors of Kohei Shitara

This figure shows the co-authorship network connecting the top 25 collaborators of Kohei Shitara. A scholar is included among the top collaborators of Kohei Shitara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kohei Shitara. Kohei Shitara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Klempner, Samuel J., Roberto Pazo-Cid, Sara Lonardi, et al.. (2025). Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study. PubMed. 7. 100131–100131. 4 indexed citations
3.
4.
Shitara, Kohei, Yung‐Jue Bang, Lucjan Wyrwicz, et al.. (2024). Neoadjuvant/adjuvant pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585.. Journal of Clinical Oncology. 42(16_suppl). 4073–4073. 2 indexed citations
5.
6.
Shen, Lin, Kohei Shitara, Jen‐Shi Chen, et al.. (2024). GEMINI-Gastric: A phase 2 study of novel treatment combinations in patients with locally advanced unresectable or metastatic gastric cancers.. Journal of Clinical Oncology. 42(16_suppl). TPS4182–TPS4182. 1 indexed citations
7.
8.
Raufi, Alexander G., Lipika Goyal, Elizabeth Smyth, et al.. (2024). CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS3163–TPS3163. 3 indexed citations
9.
Uetake, Hiroyuki, Kohei Shitara, Takayuki Yoshino, et al.. (2024). Acquired gene alteration patterns and post-progression survival: PARADIGM study analysis.. Journal of Clinical Oncology. 42(16_suppl). 3507–3507. 2 indexed citations
10.
Wainberg, Zev A., Jipan Xie, Adriana Valderrama, et al.. (2023). Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting. Clinical Cancer Research. 29(7). 1360–1367. 2 indexed citations
11.
12.
13.
Lee, Keun‐Wook, Eric Van Cutsem, Yung‐Jue Bang, et al.. (2022). Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. Clinical Cancer Research. 28(16). 3489–3498. 55 indexed citations
14.
Aoki, Hiroyasu, Satoshi Ueha, Shigeyuki Shichino, et al.. (2021). Transient Depletion of CD4+ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer. Cancer Immunology Research. 9(6). 624–636. 13 indexed citations
15.
16.
Kawazoe, Akihito, Kota Itahashi, Noboru Yamamoto, et al.. (2021). TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704). Clinical Cancer Research. 27(24). 6709–6715. 41 indexed citations
17.
Kanemitsu, Yukihide, Kohei Shitara, Junki Mizusawa, et al.. (2021). Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial. Journal of Clinical Oncology. 39(10). 1098–1107. 115 indexed citations
18.
Sasaki, Akinori, Akihito Kawazoe, Saori Mishima, et al.. (2020). Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open. 5(4). e000775–e000775. 30 indexed citations
19.
Nakao, Makoto, Keitaro Matsuo, Hidemi Ito, et al.. (2011). ABO Genotype and the Risk of Gastric Cancer, Atrophic Gastritis, and Helicobacter pylori Infection. Cancer Epidemiology Biomarkers & Prevention. 20(8). 1665–1672. 54 indexed citations
20.
Shitara, Kohei, Kei Muro, Seiji Ito, et al.. (2010). Folate Intake along with Genetic Polymorphisms in Methylenetetrahydrofolate Reductase and Thymidylate Synthase in Patients with Advanced Gastric Cancer. Cancer Epidemiology Biomarkers & Prevention. 19(5). 1311–1319. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshihiko Doi Breakdown of academic impact, for papers by Jayesh Desai Breakdown of academic impact, for papers by Josef Rüschoff Breakdown of academic impact, for papers by Kosei Hirakawa Breakdown of academic impact, for papers by Sara Lonardi Breakdown of academic impact, for papers by Akira Sawaki Breakdown of academic impact, for papers by Huamin Wang Breakdown of academic impact, for papers by Hans Prenen Breakdown of academic impact, for papers by Ho Yeong Lim Breakdown of academic impact, for papers by Andrew M. Lowy
Rankless by CCL
2026